1280P Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)

Qing Zhou(Jiangnan University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), C. Chen(BeiGene (China)), Dingzhi Huang(Tianjin Medical University Cancer Institute and Hospital), C. Fei(BeiGene (China)), Jiuwei Cui(Jilin University), Hongming Pan(Sir Run Run Shaw Hospital), Daphne Day(Monash Health), Bo Gao(Sun Yat-sen University), Xianjun Yu(Zhejiang Cancer Hospital), Lu Yang(Wuhan University), Jun Zhao(Beijing Institute of Technology), Amy Body(Monash Health), Z. Ma(Zhengzhou University), Xiao Xiang(University of Ottawa)
Annals of Oncology
September 1, 2021
10.1016/j.annonc.2021.08.1882
Cited by 2

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k